Mycosis Fungoides
📧 Sign up to get email alerts when something new happens for Mycosis Fungoides.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients [Phase 2]
A Phase 2 trial update describes dosing of Brentuximab Vedotin for patients with Mycosis fungoides and Sézary syndrome, with lymphomatoid pa…
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome [Phase 2]
Phase 2 clinical trial update evaluating pembrolizumab in combination with gemcitabine in adults with advanced mycosis fungoides or Sézary s…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT) [EARLY_Phase 1]
The PLIGHT trial, studying phototherapy combined with mogamulizumab in early-stage mycosis fungoides, has been suspended.
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome [Phase 1]
A Phase 1 clinical trial evaluating Tulmimetostat (DZR123) in patients with mycosis fungoides and Sézary syndrome; the study is currently ac…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light [Phase 2]
Phase 2 trial evaluating hypericin ointment with visible light for mycosis fungoides has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-20Clinical Trial Update: SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) [Phase 2]
Phase 2 clinical trial update for brentuximab vedotin (SGN-35) in CD30-positive lymphoproliferative disorders, including primary cutaneous a…
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Combination With Romidepsin [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating pembrolizumab in combination with romidepsin for recurrent or refractory T-cell lymphomas; the study i…
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
A real-world study reports on the use of mogamulizumab for treating cutaneous T-cell lymphoma and its subtypes.
-
CLINICAL_TRIALS trial_result · 2025-10-16Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment [Phase 1, Phase 2]
The NCI-announced Phase 1/2 trial testing magrolimab added to mogamulizumab for recurrent or refractory Mycosis Fungoides/Sezary Syndrome wa…
-
CLINICAL_TRIALS trial_result · 2025-10-09Clinical Trial Update: A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) [EARLY_Phase 1]
A first-in-human Phase 1 dose-escalation study of DT-7012, a CCR8-targeting monoclonal antibody from Domain Therapeutics, in relapsed or ref…
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas [Phase 1, Phase 2]
This is a completed Phase 1/2 clinical trial from MD Anderson evaluating AFM13 and AFM13-NK in patients with recurrent or refractory CD30-po…
-
CLINICAL_TRIALS trial_result · 2025-09-18Clinical Trial Update: Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating durvalumab with or without lenalidomide in patients with relapsed or refractory cutaneous or periph…
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL [Phase 2]
Phase 2 trial comparing HyBryte (synthetic hypericin) to Valchlor (mechlorethamine gel) for Cutaneous T-Cell Lymphoma/Mycosis Fungoides has …
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides [Phase 2]
Phase 2 trial evaluating pembrolizumab in patients with stage IB-IV mycosis fungoides and Sezary syndrome has completed, with results posted…
-
CLINICAL_TRIALS trial_result · 2025-07-18Clinical Trial Update: Ritlecitinib in CTCL [Phase 2]
A Phase 2 trial of ritlecitinib for cutaneous T-cell lymphoma was terminated.
-
CLINICAL_TRIALS trial_result · 2025-05-26Clinical Trial Update: Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer [Phase 1]
Phase 1 clinical trial evaluating direct tumor microinjection and FDG-PET to test drug sensitivity in patients with relapsed or refractory n…
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
A completed clinical trial investigated the role of large extracellular vesicles as biomarkers in various lymphomas and lymphoproliferative …
-
CLINICAL_TRIALS trial_result · 2025-01-17Clinical Trial Update: Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas [Phase 1]
Phase 1 trial update evaluating the combination of romidepsin and parsaclisib for relapsed or refractory T-cell lymphomas; the study status …
-
CLINICAL_TRIALS trial_result · 2024-08-30Clinical Trial Update: Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) [Phase 2]
Phase 2 trial evaluating maintenance treatment with resminostat in patients with advanced mycosis fungoides or Sézary syndrome has completed…
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas [Phase 1, Phase 2]
This clinical trial update covers a Phase 1/2 study of pembrolizumab plus pralatrexate in relapsed or refractory peripheral T-cell lymphomas…
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides [Phase 1, Phase 2]
Phase 1/2 study of mogamulizumab in combination with extracorporeal photopheresis for Sezary syndrome and mycosis fungoides was terminated.
-
CLINICAL_TRIALS trial_result · 2024-05-22Clinical Trial Update: Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides [NA]
This trial evaluated biodynamic imaging to predict response to gemcitabine in cutaneous T-cell lymphoma (mycosis fungoides); the study was t…
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma [Phase 2]
Phase 2 trial update reporting pharmacokinetics and ECG determinations after 8 weeks of HyBryte treatment in Cutaneous T-Cell Lymphoma/Mycos…
-
CLINICAL_TRIALS trial_result · 2023-06-05Clinical Trial Update: Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides [Phase 2]
Phase II study of AFM13 in relapsed/refractory CD30-positive T-cell lymphoma and transformed mycosis fungoides completed with results posted…
-
CLINICAL_TRIALS trial_result · 2022-10-28Clinical Trial Update: Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL [Phase 3]
Phase 3 clinical trial of naloxone hydrochloride for relief of pruritus in patients with cutaneous T-cell lymphoma (Mycosis Fungoides and Sé…